Tag: states

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”). The all-stock transaction will bring together two highly complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry.

CHANTILLY, Va., June 12, 2025 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) celebrated two station dedications on the new Foothill Gold Line light rail segment between Glendora and Pomona in Southern California’s San Gabriel Valley. The 9.1-mile segment achieved substantial completion in January, and the project has been turned over to the Los Angeles County Metropolitan Transportation Authority (Metro) for final testing, training, and preparation for passenger service, which is anticipated to begin later this year. Once operational, the new extension will be renamed, as it will be part of the 48.5-mile Metro A Line system - the longest light rail line in the country, that will carry passengers between Long Beach and Pomona.

CALGARY, Alberta, June 12, 2025 (GLOBE NEWSWIRE) -- Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) has now safely ramped up production at its Christina Lake oil sands asset following wildfire activity in the area. Production operations restarted on June 3 and production was ramped up over the course of the week.

Press release
Paris, 12 June 2025

BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.